BOTANIX PHARMACEUTICALS LTD — AGM Information 2021

Aug 26, 2021

==> picture [114 x 50] intentionally omitted <==

27 August 2021

Annual General Meeting

Philadelphia PA and Perth Australia, 27 August 2021 : Clinical dermatology and antimicrobial company, Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”), advises, in accordance with ASX Listing Rule 3.13.1, that it has scheduled the 2021 Annual General Meeting (AGM) of the Company to be held on 26 October 2021.

An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is Tuesday , 7 September 2021. Nominations must be received at the Company’s registered office no later than 5.00pm (Perth time) on Tuesday 7 September 2021.

Release authorised by

Vince Ippolito

President and Executive Chairman

For more information, please contact:

General enquiries Investor enquiries Media enquiries Corporate Communications Joel Seah Haley Chartres Botanix Pharmaceuticals Vesparum Capital H^CK P: +61 8 6555 2945 P: +61 3 8582 4800 P: +61 423 139 163 investors@botanixpharma.com botanixpharma@vesparum.com haley@hck.digital

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical studies. The Company has two separate development platforms, dermatology and antimicrobial products, both of which currently leverage the unique antiinflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a number of other product opportunities.

The Company is developing a pipeline of product candidates with recent positive data from its BTX 1801 Phase 2a antimicrobial study and plans for an upcoming Phase 2b study. For the dermatology platform, the Company has enrolled the first patient in its Phase 1b rosacea study and following a successful meeting with the FDA, the Company has confirmed a drug development plan for the BTX 1503 acne program to support registration. In addition, Botanix plans to advance its BTX 1204A atopic dermatitis program to a proof of concept canine study following encouraging early data from a pilot study.

To learn more please visit: https://www.botanixpharma.com/

==> picture [113 x 50] intentionally omitted <==

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.